<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inspiremd Inc — News on 6ix</title>
<link>https://6ix.com/company/inspiremd-inc</link>
<description>Latest news and press releases for Inspiremd Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inspiremd-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a3a078dffbe2df10a4a1.webp</url>
<title>Inspiremd Inc</title>
<link>https://6ix.com/company/inspiremd-inc</link>
</image>
<item>
<title>InspireMD to Announce First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-to-announce-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-to-announce-first-quarter-2026-financial-results</guid>
<pubDate>Mon, 27 Apr 2026 20:05:00 GMT</pubDate>
<description>MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online for</description>
</item>
<item>
<title>InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system</description>
</item>
<item>
<title>InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-to-announce-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-to-announce-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 09 Mar 2026 13:00:00 GMT</pubDate>
<description>MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording wil</description>
</item>
<item>
<title>InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-inducement-grants-under-140000179</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-inducement-grants-under-140000179</guid>
<pubDate>Tue, 20 Jan 2026 14:00:00 GMT</pubDate>
<description>MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of Janua</description>
</item>
<item>
<title>InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-publication-c-guardians-140000894</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-publication-c-guardians-140000894</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Car</description>
</item>
<item>
<title>Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting</title>
<link>https://6ix.com/company/inspiremd-inc/news/landmark-crest-2-study-published-123000214</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/landmark-crest-2-study-published-123000214</guid>
<pubDate>Mon, 24 Nov 2025 12:30:00 GMT</pubDate>
<description>Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosisMIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for c</description>
</item>
<item>
<title>InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-participate-upcoming-piper-sandler-214200458</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-participate-upcoming-piper-sandler-214200458</guid>
<pubDate>Wed, 19 Nov 2025 21:42:00 GMT</pubDate>
<description>MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the “Investor Calendar” section of the company’s website at: https://event.webcasts.com/star</description>
</item>
<item>
<title>InspireMD Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-third-quarter-2025-120000624</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-third-quarter-2025-120000624</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenueMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over</description>
</item>
<item>
<title>InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-names-peter-soukas-m-123000230</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-names-peter-soukas-m-123000230</guid>
<pubDate>Mon, 03 Nov 2025 12:30:00 GMT</pubDate>
<description>MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. “We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time</description>
</item>
<item>
<title>InspireMD to Announce Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announce-third-quarter-2025-200500745</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announce-third-quarter-2025-200500745</guid>
<pubDate>Tue, 21 Oct 2025 20:05:00 GMT</pubDate>
<description>MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by di</description>
</item>
<item>
<title>InspireMD Announces the Appointment of Dan Dearen to its Board of Directors</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-appointment-dan-dearen-120000652</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-appointment-dan-dearen-120000652</guid>
<pubDate>Wed, 17 Sep 2025 12:00:00 GMT</pubDate>
<description>MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value throu</description>
</item>
<item>
<title>InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-present-upcoming-h-c-130000222</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-present-upcoming-h-c-130000222</guid>
<pubDate>Wed, 27 Aug 2025 13:00:00 GMT</pubDate>
<description>MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10th at 10:00am Eastern Time (ET). A live audio webcast and replay of the presentation may be accessed on the “Investor Calendar” section of the company’s website at: https://inspiremd.com/investors/investor-calenda</description>
</item>
<item>
<title>InspireMD Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-second-quarter-2025-120000344</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-reports-second-quarter-2025-120000344</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid st</description>
</item>
<item>
<title>RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors</title>
<link>https://6ix.com/company/inspiremd-inc/news/rxsight-inc-appoints-raymond-w-cohen-to-its-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/rxsight-inc-appoints-raymond-w-cohen-to-its-board-of-directors-1</guid>
<pubDate>Mon, 04 Aug 2025 12:05:00 GMT</pubDate>
<description>ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. “We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical techno</description>
</item>
<item>
<title>InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-appointment-raymond-w-123100907</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-appointment-raymond-w-123100907</guid>
<pubDate>Thu, 31 Jul 2025 12:31:00 GMT</pubDate>
<description>MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. “We a</description>
</item>
<item>
<title>InspireMD Announces Combined Financings of $58 Million</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-combined-financings-58-123000381</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-combined-financings-58-123000381</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid StentMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the Company has raised approximately $58 million in combined gross proceeds through an equity private placement (“PIPE”) financing and the exercise of warrants that were triggered by the Company’s prem</description>
</item>
<item>
<title>InspireMD to Announce Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announce-second-quarter-2025-110000447</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announce-second-quarter-2025-110000447</guid>
<pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
<description>MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone</description>
</item>
<item>
<title>InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-u-commercial-launch-110000512</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-u-commercial-launch-110000512</guid>
<pubDate>Wed, 09 Jul 2025 11:00:00 GMT</pubDate>
<description>MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emboli against the</description>
</item>
<item>
<title>InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-fda-approval-cguard-200500481</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-fda-approval-cguard-200500481</guid>
<pubDate>Tue, 24 Jun 2025 20:05:00 GMT</pubDate>
<description>MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company’s C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional Course (</description>
</item>
<item>
<title>InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke</title>
<link>https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-ce-mark-approval-130000151</link>
<guid isPermaLink="true">https://6ix.com/company/inspiremd-inc/news/inspiremd-announces-ce-mark-approval-130000151</guid>
<pubDate>Fri, 13 Jun 2025 13:00:00 GMT</pubDate>
<description>MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh, CGuard is designed to reduce both</description>
</item>
</channel>
</rss>